183 related articles for article (PubMed ID: 26294726)
1. Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.
Westhrin M; Moen SH; Holien T; Mylin AK; Heickendorff L; Olsen OE; Sundan A; Turesson I; Gimsing P; Waage A; Standal T
Haematologica; 2015 Dec; 100(12):e511-4. PubMed ID: 26294726
[No Abstract] [Full Text] [Related]
2. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
3. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Giuliani N; Rizzoli V; Roodman GD
Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
[TBL] [Abstract][Full Text] [Related]
5. Myeloma and bone disease: "the dangerous tango".
Epstein J; Walker R
Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
[TBL] [Abstract][Full Text] [Related]
6. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
7. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
8. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
9. [Expression of serum GDF15 and its clinical significance in multiple myeloma patients].
Zhao N; Yang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Mar; 39(3):270-5. PubMed ID: 24748192
[TBL] [Abstract][Full Text] [Related]
10. The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis.
Uchiyama T; Kawabata H; Miura Y; Yoshioka S; Iwasa M; Yao H; Sakamoto S; Fujimoto M; Haga H; Kadowaki N; Maekawa T; Takaori-Kondo A
Cancer Med; 2015 Oct; 4(10):1558-72. PubMed ID: 26276681
[TBL] [Abstract][Full Text] [Related]
11. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.
Ehrlich LA; Chung HY; Ghobrial I; Choi SJ; Morandi F; Colla S; Rizzoli V; Roodman GD; Giuliani N
Blood; 2005 Aug; 106(4):1407-14. PubMed ID: 15878977
[TBL] [Abstract][Full Text] [Related]
12. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.
Raimondi L; De Luca A; Amodio N; Manno M; Raccosta S; Taverna S; Bellavia D; Naselli F; Fontana S; Schillaci O; Giardino R; Fini M; Tassone P; Santoro A; De Leo G; Giavaresi G; Alessandro R
Oncotarget; 2015 May; 6(15):13772-89. PubMed ID: 25944696
[TBL] [Abstract][Full Text] [Related]
13. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.
Brunetti G; Rizzi R; Oranger A; Gigante I; Mori G; Taurino G; Mongelli T; Colaianni G; Di Benedetto A; Tamma R; Ingravallo G; Napoli A; Faienza MF; Mestice A; Curci P; Specchia G; Colucci S; Grano M
Oncotarget; 2014 Dec; 5(24):12950-67. PubMed ID: 25460501
[TBL] [Abstract][Full Text] [Related]
14. CCL20 chemokine induces both osteoblast proliferation and osteoclast differentiation: Increased levels of CCL20 are expressed in subchondral bone tissue of rheumatoid arthritis patients.
Lisignoli G; Piacentini A; Cristino S; Grassi F; Cavallo C; Cattini L; Tonnarelli B; Manferdini C; Facchini A
J Cell Physiol; 2007 Mar; 210(3):798-806. PubMed ID: 17133360
[TBL] [Abstract][Full Text] [Related]
15. Microtubule assembly affects bone mass by regulating both osteoblast and osteoclast functions: stathmin deficiency produces an osteopenic phenotype in mice.
Liu H; Zhang R; Ko SY; Oyajobi BO; Papasian CJ; Deng HW; Zhang S; Zhao M
J Bone Miner Res; 2011 Sep; 26(9):2052-67. PubMed ID: 21557310
[TBL] [Abstract][Full Text] [Related]
16. [Regulation of osteoclastogenesis by osteocytes through growth differentiation factor-15].
Hinoi E
Yakugaku Zasshi; 2014; 134(12):1259-63. PubMed ID: 25452236
[TBL] [Abstract][Full Text] [Related]
17. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.
Gu Z; Wang H; Xia J; Yang Y; Jin Z; Xu H; Shi J; De Domenico I; Tricot G; Zhan F
Cancer Res; 2015 Jun; 75(11):2211-21. PubMed ID: 25855377
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease.
Fu R; Peng F; Liu H; Wang Y; Li L; Wang G; Song J; Shao Z
Ann Hematol; 2016 Jun; 95(7):1099-106. PubMed ID: 27118542
[TBL] [Abstract][Full Text] [Related]
19. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
[TBL] [Abstract][Full Text] [Related]
20. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Chauhan D; Munshi NC; Richardson PG; Anderson KC
Br J Haematol; 2007 Oct; 139(1):55-63. PubMed ID: 17854307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
